Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PORT-6 + PORT-7 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Portage Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PORT-6 + PORT-7 + pembrolizumab is a combination immunotherapy regimen being developed by Portage Biotech in collaboration with Merck. The combination consists of two small molecule adenosine receptor antagonists—PORT-6 (formerly TT-10), which targets the adenosine 2A receptor (A2AR), and PORT-7 (formerly TT-4), which targets the adenosine 2B receptor (A2BR)—alongside the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda). This therapeutic strategy aims to overcome adenosine-mediated immunosuppression within the tumor microenvironment, thereby enhancing the anti-tumor activity of PD-1 checkpoint blockade. The combination is currently being evaluated in the ADPORT-601 Phase 1a/1b clinical trial, specifically targeting patients with 'adenosine-high' solid tumors, including non-small cell lung, prostate, renal, head and neck, colorectal, endometrial, and ovarian cancers.
- Brand names
- Keytruda
- Other names
- TT-10 + TT-4 + KeytrudaPORT-6 + PORT-7 + KeytrudaPORT-6/7 combo + Keytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on PORT-6 + PORT-7 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PORT-6 + PORT-7 + pembrolizumab.